Advanced in Neuroblastoma

Dr. James L. Gulley

Hematology Oncology
10 Center Dr., 8b08, Msc 1750, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Neuroblastoma
10 Center Dr., 8b08, Msc 1750, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Gulley is a Hematologist Oncology provider in Bethesda, Maryland. Dr. Gulley is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Prostate Cancer, Olfactory Neuroblastoma, Chordoma, Urothelial Cancer, and Orchiectomy.

His clinical research consists of co-authoring 278 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Neuroblastoma.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

10 Center Dr., 8b08, Msc 1750, Bethesda, MD 20892

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Biospecimen Acquisition From Human Subjects
Biospecimen Acquisition From Human Subjects
Enrollment Status: Recruiting
Publish Date: September 24, 2025
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Enrollment Status: Recruiting
Publish Date: September 04, 2025
Intervention Type: Drug, Biological
Study Drugs: Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib
Study Phase: Phase 1
Data Collection, Clinical Care and Interventions in CCR, NCI
Data Collection, Clinical Care and Interventions in CCR, NCI
Enrollment Status: Enrolling_by_invitation
Publish Date: October 07, 2025
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
Enrollment Status: Completed
Publish Date: April 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Nivolumab, Ipilimumab, PROSTVAC Shared Antigen Vaccine, Neoantigen DNA Vaccine
Study Phase: Phase 1
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials

278 Total Publications

REMOVED: Referral Patterns and Barriers to Enrollment on a Trial Using HLA-A*02:01-Restricted E7 T Cell Receptor (TCR)-T Cells for Human Papillomavirus (HPV)-Associated Malignancies.
REMOVED: Referral Patterns and Barriers to Enrollment on a Trial Using HLA-A*02:01-Restricted E7 T Cell Receptor (TCR)-T Cells for Human Papillomavirus (HPV)-Associated Malignancies.
Journal: Transplantation and cellular therapy
Published: July 05, 2025
Similar Doctors
Advanced in Neuroblastoma
Dr. Huzefa F. Bahrain
Hematology Oncology | Oncology
Advanced in Neuroblastoma
Dr. Huzefa F. Bahrain
Hematology Oncology | Oncology

Auerbach Hematology Oncology Associates P C

5233 King Ave, Suite 308, 
Baltimore, MD 
 (41.9 miles away)
410-780-4050
Languages Spoken:
English, Hindi, Japanese
See accepted insurances
Accepting New Patients

Huzefa Bahrain is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Bahrain is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Hereditary Neuroblastoma, and Neuroblastoma. Dr. Bahrain is currently accepting new patients.

Experienced in Neuroblastoma
Dr. Ann W. Gramza
Hematology Oncology | Hematology | Oncology
Experienced in Neuroblastoma
Dr. Ann W. Gramza
Hematology Oncology | Hematology | Oncology
3800 Reservoir Rd Nw, 
Washington, DC 
 (6.5 miles away)
202-444-1558
Languages Spoken:
English
See accepted insurances

Ann Gramza is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Dr. Gramza is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. Her top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, and Laryngeal Cancer.

Experienced in Neuroblastoma
Dr. John F. Deeken
Oncology | Hematology Oncology
Experienced in Neuroblastoma
Dr. John F. Deeken
Oncology | Hematology Oncology

Inova Health Care Services

8081 Innovation Park Dr, 
Fairfax, VA 
 (11.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Deeken is an Oncologist and a Hematologist Oncology provider in Fairfax, Virginia. Dr. Deeken is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Oral Squamous Cell Carcinoma. Dr. Deeken is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gulley's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile